opportunities available to pharmaceutical firms confronted with the loss of patent protection on their branded drug. The marketing … through government regulators such as the US Food and Drug Administration. These options are then considered in the context of …

after the entry of generics. Some jurisdictions control this by mandating doctors to prescribe the generic drug; other …

affect concentration in drug markets. We estimate the model using data collated from six disparate sources. We find that …

During patent litigation, pay-for-delay deals involve a payment from a patent holder of a branded drug to a generic … drug manufacturer to delay entry and withdraw the patent challenge. In return for staying out of the market, the generic …

trials to identify the effect of drug pipeline pressure on the prices of incumbent drugs. Results suggest that pipeline …Economic literature has extensively studied how prices for incumbent pharmaceutical drugs respond to generic …. We contribute to this gap in the literature by both developing a model of pricing strategies for incumbent drug …

that allows for competition between the brand drug and generics, and among multiple generic drugs. The model accommodates … the effects of prices, detailing, sampling, journal advertising, time-in-market, and molecule-specific characteristics …. The model is estimated on cross-section time-series data for 49 molecules in which the brand drug lost patent exclusivity …